All News Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-21 EDT			5-day change	1st Jan Change
4.25 ^USD	-2.75%		+4.68%	-67.16%

04-16	Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-11	North American Morning Briefing : Stock Futures -2-	DJ

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Windtree Therapeutics Regains Compliance with Nasdaq	05-07	AQ
Windtree Therapeutics : April'24 Corporate Presentation	04-24	PU
Reverse Split: 1 of 18	04-21	FA
Windtree Therapeutics Announces Reverse Stock Split	04-18	AQ
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates	04-17	AQ
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
North American Morning Briefing : Stock Futures -2-	04-11	DJ
Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call	04-10
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	04-09	MT
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing	04-08	AQ
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding	04-07	CI
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	04-07	CI
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding	04-01	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer	02-16	CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	02-16	CI
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	02-01	AQ
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	02-01	CI
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	01-31	CI
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives	01-31	AQ
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company	01-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

All News

Filters